Latest News
David Rimm, MD, PhD, from Yale Cancer Center discussed new study results at SABCS which identified quantitative multiplex immunofluorescence assay as an optimal way to detect TROP2 and HER2 expression among patients with breast cancer.
- December 07, 2023Source: The ASCO Post
A novel selective biomarker (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented at the 2023 San Antonio Breast Cancer Symposium.
- December 04, 2023
A team of researchers led by senior author Dr. David Rimm and first author Charles “Jack” Robbins at Yale Cancer Center evaluated a new “selective” biomarker called Troplex™, which assesses HER2, TROP2, and cytokeratin using quantitative immunofluorescence.
- November 28, 2023
The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples.
- November 28, 2023
Yale Cancer Center researchers at Yale School of Medicine will present new research at the 46th annual San Antonio Breast Cancer Symposium (SABCS) from December 5 to 9.
- October 12, 2023
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its $60.2 million commitment to fund breast cancer research in 2023-2024, supporting more than 250 scientists at leading academic and medical institutions, including eight grants at Yale Cancer Center and Smilow Cancer Hospital.
- September 08, 2023
The study's findings suggest that NC318, both alone and in combination with pembrolizumab, improved response rates and clinical outcomes for some patients with NSCLC.
- August 03, 2023
A research team co-led by Dr. Katerina Politi found how mSWI/SNF complexes mediate resistance of lung adenocarcinomas to osimertinib and other tyrosine kinase inhibitors.
- June 09, 2023Source: MedPage Today
David Rimm, MD, PhD, an Anthony N. Brady Professor of Pathology at Yale, discusses if pathologists are adequately quantifying the HER2 immunohistochemistry assay.
- May 18, 2023
Yale Cancer Center and Smilow Cancer Hospital scientists and clinicians will present new research at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 2nd to June 6th at McCormick Place in Chicago, Illinois. This year’s scientific program will feature more than 2,900 abstracts, covering all major diseases and research areas, including breast, lung, head and neck, gynecological, prostate, and gastric cancers.